Empowering People to be Ambassadors of their Own Health Since 1997.


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, January 2015


A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection. Burton MJ1, Penman A, Sunesara I, McGuire BM, Hook EW 3rd. Am J Med Sci. 2014 Dec;348(6):455-9. doi: 10.1097/MAJ.0000000000000321.

Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies. Scott J1, Gilles L, Fu M, et al. J Viral Hepat. 2014 Dec 9. doi: 10.1111/jvh.12365. [Epub ahead of print]

Patients treated with first-generation HCV protease inhibitors exhibits high ribavirin concentrations. Bodeau S1, Nguyen-Khac E, Solas C, Bennis Y, Capron D, Duverlie G, Brochot E. J Clin Pharmacol. 2014 Dec 23. doi: 10.1002/jcph.454. [Epub ahead of print]

Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment. Young AM1, Stephens DB2, Khaleel HA3, Havens JR4. Contemp Clin Trials. 2014 Dec 29. pii: S1551-7144(14)00200-6. doi: 10.1016/j.cct.2014.12.015. [Epub ahead of print]

The Combination of Simeprevir and Sofosbuvir is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients with Hepatitis C-related Child’s Class A Cirrhosis. Pearlman BL1, Ehleben C2, Perrys M3. Gastroenterology. 2014 Dec 31. pii: S0016-5085(14)01579-0. doi: 10.1053/j.gastro.2014.12.027. [Epub ahead of print]

Influence of Hepatitis C Virus and IL28B Genotypes on Liver Stiffness. Lundbo LF1, Clausen LN1, Weis N2, Schønning K3, Rosenørn L4, Benfield T1, Christensen PB5. PLoS One. 2014 Dec 29;9(12):e115882. doi: 10.1371/journal.pone.0115882. eCollection 2014.

Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. Tsui JI1, Evans JL2, Lum PJ3, Hahn JA4, Page K5. JAMA Intern Med. 2014 Dec 1;174(12):1974-81. doi: 10.1001/jamainternmed.2014.5416.

Incidence of virological failure and emergence of resistance with twice-daily vs every 8-h administration of telaprevir in the OPTIMIZE study. Dierynck I1, Ghys A, Witek J, et al. J Viral Hepat. 2014 Dec;21(12):835-42. doi: 10.1111/jvh.12347.

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. Masaki N1, Sugiyama M, Shimada N, et al. J Gastroenterol Hepatol. 2014 Dec;29(12):1996-2005. doi: 10.1111/jgh.12646.

Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. Nakagawa A1, Atsukawa M, Tsubota A, et al. Eur J Gastroenterol Hepatol. 2014 Dec;26(12):1329-34. doi: 10.1097/MEG.0000000000000228.

Differential Antiviral Effects of Pegylated Interferon-α2a and Pegylated Interferon-α 2b in Chronic Hepatitis C. Durante-Mangoni E1, Parrella A, Iossa D, et al. Clin Drug Investig. 2014 Dec;34(12):871-8. doi: 10.1007/s40261-014-0241-y.

Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Cho YK1, Kim YN1, Song BC1. Clin Mol Hepatol. 2014 Dec;20(4):368-75. doi: 10.3350/cmh.2014.20.4.368. Epub 2014 Dec 24.

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Reddy KR1, Zeuzem S2, Zoulim F3, et al. Lancet Infect Dis. 2015 Jan;15(1):27-35. doi: 10.1016/S1473-3099(14)71002-3. Epub 2014 Dec 5.


Diffusion of Information throughout the Host Interactome Reveals Gene Expression Variations in Network Proximity to Target Proteins of Hepatitis C Virus. Mosca E1, Alfieri R1, Milanesi L1. PLoS One. 2014 Dec 2;9(12):e113660. doi: 10.1371/journal.pone.0113660. eCollection 2014.

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir. Friborg J1, Zhou N, Han Z, Yang X, Falk P, Mendez P, McPhee F. Infect Dis Ther. 2014 Dec 17. [Epub ahead of print]

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-naïve Patients with Chronic Hepatitis C and Advanced Liver Fibrosis/Cirrhosis. Zeuzem S1, Soriano V2, Asselah T3, et al. Antimicrob Agents Chemother. 2014 Dec 15. pii: AAC.04383-14. [Epub ahead of print]

The interaction between the Hepatitis C proteins NS4B and NS5A is involved in viral replication. David N1, Yaffe Y2, Hagoel L1, et al. Virology. 2015 Jan 15;475:139-49. doi: 10.1016/j.virol.2014.10.021. Epub 2014 Dec 2.

Dual effects of duplex RNA harboring 5′-terminal triphosphate on gene silencing and RIG-I mediated innate immune response. Baek SE1, Kim H1, Kim KB1, et al. Biochem Biophys Res Commun. 2015 Jan 9;456(2):591-7. doi: 10.1016/j.bbrc.2014.11.119. Epub 2014 Dec 6.

Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. King LY1, Johnson KB1, Zheng H2, et al. PLoS One. 2014 Dec 12;9(12):e114747. doi: 10.1371/journal.pone.0114747. eCollection 2014.

Amphipathic α-Helices in Apolipoproteins Are Crucial to the Formation of Infectious Hepatitis C Virus Particles. Fukuhara T1, Wada M1, Nakamura S2, et al. PLoS Pathog. 2014 Dec 11;10(12):e1004534. doi: 10.1371/journal.ppat.1004534. eCollection 2014.

Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Hao C1, Zhou Y, He Y, et al. Immunology. 2014 Dec;143(4):531-8. doi: 10.1111/imm.12330.

Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment. Yalcin AD1, Celik B1, Kose S1, Seyman D1, Gumuslu S1, Yalcin AN1. Infez Med. 2014 Dec 1;22(4):283-7.

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation. Sabo JP1, Kort J, Ballow C, et al. J Clin Pharmacol. 2014 Dec 1. doi: 10.1002/jcph.436. [Epub ahead of print]

Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Ma L1, Zhou Y, Zhang Y, Li Y, et al. Immunology. 2014 Dec;143(4):670-8. doi: 10.1111/imm.12350.

Cytokines and HCV-related autoimmune disorders. Antonelli A1, Ferrari SM, Ruffilli I, Fallahi P. Immunol Res. 2014 Dec;60(2-3):311-9. doi: 10.1007/s12026-014-8569-1.

Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. Riva E1, Scagnolari C, Turriziani O, Antonelli G. Clin Microbiol Infect. 2014 Dec;20(12):1237-45. doi: 10.1111/1469-0691.12797. Epub 2014 Dec 12.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. Pilot-Matias T1, Tripathi R2, Cohen D2, et al. Antimicrob Agents Chemother. 2014 Dec 1. pii: AAC.04227-14. [Epub ahead of print]

CD100 Up-Regulation Induced by Interferon-α on B Cells Is Related to Hepatitis C Virus Infection. He Y1, Guo Y1, Zhou Y1, et al. PLoS One. 2014 Dec 1;9(12):e113338. doi: 10.1371/journal.pone.0113338. eCollection 2014.


Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Sangal RB1, Taylor LE, Gillani F, Poppas A, Klinger JR, Ventetuolo CE. Ann Am Thorac Soc. 2014 Dec;11(10):1553-9. doi: 10.1513/AnnalsATS.201405-225OC.

Will a quadruple multiplexed point-of-care screening strategy for HIV-related co-infections be feasible and impact detection of new co-infections in at-risk populations? Results from cross-sectional studies. Pai NP1, Dhurat R2, Potter M3, et al. BMJ Open. 2014 Dec 15;4(12):e005040. doi: 10.1136/bmjopen-2014-005040.

Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. Neukam K1, Munteanu D, Haubitz S, et al. Antivir Ther. 2014 Dec 3. doi: 10.3851/IMP2921. [Epub ahead of print]

Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004-2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. Sobrino-Vegas P1, Monge Corella S1, et al. PLoS One. 2014 Dec 30;9(12):e116226. doi: 10.1371/journal.pone.0116226. eCollection 2014.

GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection. Blackard JT1, Ma G1, Welge JA2, et al. PLoS One. 2014 Dec 10;9(12):e114467. doi: 10.1371/journal.pone.0114467. eCollection 2014.

Single nucleotide polymorphisms of CXCL9-11 chemokines are associated with liver fibrosis in HIV/HCV-coinfected patients. Pineda-Tenor D1, Berenguer J, García-Álvarez M, et al. J Acquir Immune Defic Syndr. 2014 Dec 31. [Epub ahead of print]

Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term. Macías J1, Mancebo M, Márquez M, et al. Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print]

Cryptococcosis in Patients Living with Hepatitis C and B Viruses. Spies FS1, de Oliveira MB, Krug MS, Severo CB, Severo LC, Vainstein MH. Mycopathologia. 2014 Dec 21. [Epub ahead of print]

Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Clifford DB1, Vaida F2, Kao YT2, et al. Neurology. 2014 Dec 10. pii: 10.1212/WNL.0000000000001156. [Epub ahead of print]



Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Jardim AC1, Igloi Z2, Shimizu JF3, et al. Antiviral Res. 2014 Dec 31. pii: S0166-3542(14)00369-6. doi: 10.1016/j.antiviral.2014.12.018. [Epub ahead of print]

Supercritical fluid extraction of heather (Calluna vulgaris) and evaluation of anti-hepatitis C virus activity of the extracts. García-Risco MR1, Vázquez E1, Sheldon J2, et al. Virus Res. 2014 Dec 27. pii: S0168-1702(14)00536-X. doi: 10.1016/j.virusres.2014.12.022. [Epub ahead of print]


Decreased delta sleep ratio and elevated alpha power predict vulnerability to depression during interferon-alpha treatment. Lotrich FE1, Germain A1. Acta Neuropsychiatr. 2014 Dec 1:1-11. [Epub ahead of print]

Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Klimas J1, Tobin H, Field CA, et al. Cochrane Database Syst Rev. 2014 Dec 3;12:CD009269. doi: 10.1002/14651858.CD009269.pub3.

Cognitive function and endogenous cytokine levels in children with chronic hepatitis C. Abu Faddan NH1, Shehata GA, Abd Elhafeez HA, et al. J Viral Hepat. 2014 Dec 15. doi: 10.1111/jvh.12373. [Epub ahead of print]

Study of pruritus in chronic hepatitis C patients. Suzuki K1, Tamano M1, Katayama Y1, et al. World J Gastroenterol. 2014 Dec 21;20(47):17877-82. doi: 10.3748/wjg.v20.i47.17877.

Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Benstead TJ1, Chalk CH, Parks NE. Cochrane Database Syst Rev. 2014 Dec 20;12:CD010404. doi: 10.1002/14651858.CD010404.pub2.

Association of hepatitis C virus infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Molnar MZ1, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar-Zadeh K, Kovesdy CP. Hepatology. 2014 Dec 20. doi: 10.1002/hep.27664. [Epub ahead of print]

Magnetic resonance sialography of the parotid glands in chronic hepatitis C virus patients with and without vasculitis. Shahin AA1, Hussein H, Gaber W, Elbaz T, Salah El Din LA. Int J Rheum Dis. 2014 Dec 23. doi: 10.1111/1756-185X.12493. [Epub ahead of print]

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Siederdissen CH1, Maasoumy B, Deterding K, et al. Liver Int. 2014 Dec 30. doi: 10.1111/liv.12774. [Epub ahead of print]

Normocaloric low cholesterol diet modulates th17/treg balance in patients with chronic hepatitis C virus infection. Maggio R1, Viscomi C2, Andreozzi P3, et al. PLoS One. 2014 Dec 22;9(12):e112346. doi: 10.1371/journal.pone.0112346. eCollection 2014.

Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence. Henderson RR1, Visaria J, Bridges GG, Dorholt M, Levin RJ, Frazee SG. J Manag Care Pharm. 2014 Dec;20(12):1227-34.

Vitamin D deficiency in chronic liver disease. Iruzubieta P1, Terán Á1, Crespo J1, Fábrega E1. World J Hepatol. 2014 Dec 27;6(12):901-15. doi: 10.4254/wjh.v6.i12.901.

HIV and Hepatitis C Mortality in Massachusetts, 2002-2011: Spatial Cluster and Trend Analysis of HIV and HCV Using Multiple Cause of Death. Meyers DJ1, Hood ME2, Stopka TJ3. PLoS One. 2014 Dec 11;9(12):e114822. doi: 10.1371/journal.pone.0114822. eCollection 2014.


Increased DNA damage in hepatitis C virus-related hepatocellular carcinoma. Shawki SM1, Meshaal SS, El Dash AS, Zayed NA, Hanna MO. DNA Cell Biol. 2014 Dec;33(12):884-90. doi: 10.1089/dna.2014.2417.

Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response. Pinzone MR1, Zanghì AM, Rapisarda L, et al. Eur Rev Med Pharmacol Sci. 2014 Dec;18(2 Suppl):11-5.

Metastasis to the jaws as a first manifestation of hepatocellular carcinoma: Report of a case and analysis of 41 cases. Pesis M, Taicher S1, Greenberg G2, Hirshberg A3. J Craniomaxillofac Surg. 2014 Dec;42(8):1997-2001. doi: 10.1016/j.jcms.2014.09.005. Epub 2014 Sep 19.

Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. Kim JH1, Sohn BH2, Lee HS2, et al. PLoS Med. 2014 Dec 23;11(12):e1001770. doi: 10.1371/journal.pmed.1001770. eCollection 2014.

MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Peveling-Oberhag J1, Seiz A2, Döring C3, et al. Transl Oncol. 2014 Dec;7(6):672-80. doi: 10.1016/j.tranon.2014.09.003.

The Effect of HIV Viral Control on the Incidence of Hepatocellular Carcinoma in Veterans with Hepatitis C and HIV Coinfection. Kramer JR1, Kowalkowski MA, Duan Z, Chiao EY. J Acquir Immune Defic Syndr. 2014 Dec 31. [Epub ahead of print]

Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. Bahnassy AA1, Zekri AR1, El-Bastawisy A1, et al. World J Gastroenterol. 2014 Dec 28;20(48):18240-8. doi: 10.3748/wjg.v20.i48.18240.

Mitochondrial iron accumulation exacerbates hepatic toxicity caused by hepatitis C virus core protein. Sekine S1, Ito K1, Watanabe H1, et al. Toxicol Appl Pharmacol. 2014 Dec 27. pii: S0041-008X(14)00442-6. doi: 10.1016/j.taap.2014.12.004. [Epub ahead of print]

Evaluation of hepatocellular carcinoma development in patients with chronic hepatitis C by EOB-MRI. Nojiri S1, Fujiwara K1, Shinkai N1, Endo M1, Joh T1. World J Hepatol. 2014 Dec 27;6(12):930-8. doi: 10.4254/wjh.v6.i12.930.

Clinical implication of the preoperative GSA index in 99mTc-GSA scintigraphy in hepatitis C virus-related hepatocellular carcinoma. Nishikawa H1, Osaki Y1, Komekado H1, et al. Oncol Rep. 2014 Dec 22. doi: 10.3892/or.2014.3691. [Epub ahead of print]

Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib. Okuyama H1, Ikeda M, Kuwahara A, et al. Oncology. 2014 Dec 11;88(4):241-246. [Epub ahead of print]

Surgical Outcomes of Hepatic Resection for Hepatitis B Virus Surface Antigen-Negative and Hepatitis C Virus Antibody-Negative Hepatocellular Carcinoma. Yamashita YI1, Imai D, Bekki Y, et al. Ann Surg Oncol. 2014 Dec 4. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)